Biotech News

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Arcutis Biotherapeutics (ARQT)Arcutis Biotherapeutics2026-10-06 12:20 ESTCompany update

Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award ZORYVE is the number one prescribed branded topical therapy

Related news

ARQTArcutis Biotherapeutics2026-07-08 12:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

ARQTArcutis Biotherapeutics2026-06-30 13:16 EST

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

View all latest news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-10-06 12:20 EST

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

ARQTArcutis Biotherapeutics2026-10-02 20:00 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-09-29 13:15 EST

Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options

ARQTArcutis Biotherapeutics2026-09-04 20:00 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-09-02 20:00 EST

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Stock data

Close: 23.92 USD
Market cap: 2.6B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States